ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

Search

Johnson and Johnson

Chiusa

SettoreSettore sanitario

186.77 -1.86

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

186.58

Massimo

190.27

Metriche Chiave

By Trading Economics

Entrata

-5.5B

5.5B

Vendite

250M

24B

P/E

Media del settore

18.663

37.461

EPS

2.8

Rendimento da dividendi

2.63

Margine di Profitto

23.321

Dipendenti

138,100

EBITDA

-1.2B

7.5B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+8.5% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

2.63%

2.33%

Prossima data del Dividendo

9 dic 2025

Prossima data del' Ex Dividendo

25 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

6.8B

467B

Apertura precedente

188.63

Chiusura precedente

186.77

Notizie sul Sentiment di mercato

By Acuity

36%

64%

111 / 373 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Johnson and Johnson Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 ott 2025, 10:35 UTC

Utili

J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains

14 ott 2025, 10:51 UTC

Discorsi di Mercato
Utili

J&J Sales Get Boost From Tremfya Drug -- Market Talk

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson Raises 2025 View To Sales $93.5B-$93.9B Vs Prior View $93.2B-$93.6B >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson Now Sees 2025 Operational Sales of $93B-$93.4B Vs Prior Range $92.7B-$93.1B >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson Now Sees 2025 Adjusted Operational Sales Growth of 3.5%-4% Vs Prior Outlook 3.2%-3.7% >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson Backs 2025 Adj EPS $10.80-Adj EPS $10.90 >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q Worldwide MedTech Sales $8.43B >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson: 3Q MedTech Business Delivered Operational Sales Grew 5.6%, Driven Primarily by Electrophysiology Products, Abiomed, Shockwave, Wound Closure Pdts and Surgical Vision >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson: 3Q Innovative Medicine Operational Sales Grew 5.3%, With Net Acquisitions and Divestitures Positively Affecting Growth by 1.6% Due to Caplyta >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q International Sales $10.29B >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson Still Sees 2025 Adjusted Operational EPS $10.63-$10.73 >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson: Increasing 2025 Operational Sales Growth to Be in Range of 4.8%-5.3% Vs Prior Range 4.5%-5% >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson: 3Q Innovative Medicine Operational Sales Growth Driven by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya, Simponi/Simponi Aria and Spravato >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q Adj EPS $2.80 >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q Orthopaedics Sales $2.27B >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q Worldwide Innovative Medicine Sales $15.56B >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q U.S. Sales $13.71B >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q Sales $23.99B >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q EPS $2.12 >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q Orthopaedics Sales $2.27B >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q EPS $2.12 >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q Worldwide MedTech Sales $8.43B >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q U.S. Sales $13.71B >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q International Sales $10.29B >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q Worldwide Innovative Medicine Sales $15.56B >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q Net $5.15B >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q Adj EPS $2.80 >JNJ

14 ott 2025, 10:20 UTC

Utili

Johnson & Johnson 3Q Sales $23.99B >JNJ

14 ott 2025, 10:03 UTC

Azioni calde

Stocks to Watch Tuesday: JPMorgan, Goldman Sachs, Ford -- WSJ

10 ott 2025, 16:19 UTC

Acquisizioni, Fusioni, Takeovers

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Johnson and Johnson Previsione

Obiettivo di Prezzo

By TipRanks

8.5% in crescita

Previsioni per 12 mesi

Media 206.47 USD  8.5%

Alto 225 USD

Basso 176 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Johnson and Johnson - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

19 ratings

12

Acquista

7

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

154.93 / 155.895Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

111 / 373 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
help-icon Live chat